|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.36 USD | -6.44% |
|
-6.89% | +26.92% |
| 15/01 | MBX Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM | |
| 12/01 | Mbx Biosciences says phase 3 trial of canvuparatide to start in Q3 2026 | RE |
| Capitalization | 193.71Cr 165.62Cr 153.74Cr 144.19Cr 267.5Cr 18TCr 286.44Cr 1.76TCr 698.22Cr 8.39TCr 726.41Cr 711.55Cr 31TCr | P/E ratio 2025 * |
-16.8x | P/E ratio 2026 * | -14.3x |
|---|---|---|---|---|---|
| Enterprise value | 162.23Cr 138.71Cr 128.76Cr 120.76Cr 224.03Cr 15TCr 239.89Cr 1.48TCr 584.77Cr 7.02TCr 608.37Cr 595.93Cr 26TCr | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
96.76% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: MBX Biosciences, Inc.
More recommendations
More press releases
| 1 day | -6.43% | ||
| 1 week | -6.89% | ||
| Current month | +26.92% | ||
| 1 month | +15.03% | ||
| 3 months | +161.46% | ||
| 6 months | +228.38% | ||
| Current year | +26.92% |
| 1 week | 39.27 |  | 44.89 |
| 1 month | 27.84 | | 44.89 |
| Current year | 27.84 | | 44.89 |
| 1 year | 4.81 | | 44.89 |
| 3 years | 4.81 | | 44.89 |
| 5 years | 4.81 | | 44.89 |
| 10 years | 4.81 | | 44.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter Hawryluk
CEO | Chief Executive Officer | 57 | 01/01/2020 |
Rick Bartram
DFI | Director of Finance/CFO | 45 | 01/04/2022 |
Stewart Hallett
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Hawryluk
CHM | Chairman | 57 | 01/01/2020 |
| Director/Board Member | 66 | 01/07/2020 | |
Patrick Heron
BRD | Director/Board Member | 55 | 01/07/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.44% | -6.89% | +291.30% | - | 193.71Cr | |
| +2.54% | -0.11% | -2.24% | +12.61% | 4.83TCr | |
| +3.56% | -0.61% | +16.62% | +4.87% | 3.98TCr | |
| +2.29% | -2.17% | +55.12% | +26.11% | 3.7TCr | |
| -1.45% | -7.69% | +17.41% | +37.09% | 3.07TCr | |
| +0.88% | -3.36% | +191.71% | +326.31% | 2.25TCr | |
| +3.25% | +0.24% | +77.80% | +157.97% | 1.7TCr | |
| Average | +0.60% | +0.08% | +92.53% | +94.16% | 2.82TCr | |
| Weighted average by Cap. | +1.77% | -3.03% | +47.25% | +66.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -9.49Cr -8.12Cr -7.54Cr -7.07Cr -13Cr -869.62Cr -14Cr -86Cr -34Cr -411Cr -36Cr -35Cr -1.5TCr | -14Cr -12Cr -11Cr -10Cr -19Cr -1.24TCr -20Cr -123.8Cr -49Cr -588.4Cr -51Cr -50Cr -2.15TCr |
| Net Debt | -31Cr -27Cr -25Cr -23Cr -43Cr -2.88TCr -47Cr -286.71Cr -113.46Cr -1.36TCr -118.04Cr -115.62Cr -4.98TCr | -24Cr -21Cr -19Cr -18Cr -33Cr -2.21TCr -36Cr -219.98Cr -87Cr -1.05TCr -91Cr -89Cr -3.82TCr |
More financial data
* Estimated data
Employees
43
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | 40.03 $ | -7.21% | 4,11,170 |
| 20/26/20 | 43.14 $ | +6.44% | 7,74,455 |
| 16/26/16 | 40.53 $ | -0.93% | 5,04,308 |
| 15/26/15 | 40.91 $ | -4.84% | 10,61,043 |
| 14/26/14 | 42.99 $ | +18.40% | 14,25,501 |
Delayed Quote Nasdaq, January 22, 2026 at 12:45 am IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
43.14USD
Average target price
60.56USD
Spread / Average Target
+40.37%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MBX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition